RxDoctor Payments Data

Robert Magley, MD

Sports Medicine · Ebensburg, PANPI 1013945047

Payments from drug & device makers

$348in general payments, 2019–2025

Across 22 payments — averaging $15.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$170
  • AstraZeneca$86
  • Genentech USA, Inc.$42
  • Bayer$15
  • Amgen$12
  • Lilly USA, LLC$12
  • plus $11 from 1 others

What the payments were for

  • Food & beverage$33697%
  • Education$123%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk10$170
AstraZeneca6$86
Genentech USA, Inc.2$42
Bayer1$15
Amgen1$12
Lilly USA, LLC1$12
GSK1$11

How this compares

$348 in reported general payments places this provider in the 35th percentile of 311 sports medicine providers in Pennsylvania.

See all sports medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$66,589
Medicare patients
74
Services billed
1,854

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide148$170,766
EliquisApixaban130$110,638
JardianceEmpagliflozin71$74,123
JanuviaSitagliptin Phosphate16$25,415
XareltoRivaroxaban14$20,012
TradjentaLinagliptin16$13,534
MounjaroTirzepatide13$13,281
MyrbetriqMirabegron19$9,960
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$9,039
Breo ElliptaFluticasone/Vilanterol14$8,282
Montelukast Sodium271$6,933
Atorvastatin Calcium459$4,873
Levothyroxine Sodium411$4,622
Losartan Potassium300$4,550
Pantoprazole Sodium241$4,476

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$170$170,766148 claims
GSKTrelegy Ellipta, Breo Ellipta$11$17,32029 claims
Lilly USA, LLCMounjaro$12$13,28113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 311 sports medicine providers in Pennsylvania.

Other sports medicine in Ebensburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →